Literature DB >> 33926176

Pneumothorax and pneumomediastinum in COVID-19 acute respiratory distress syndrome.

Amos Lal1, Ajay Kumar Mishra2, Jamal Akhtar3, Christoph Nabzdyk4.   

Abstract

COVID-19 has involved numerous countries across the globe and the disease burden, susceptible age group; mortality rate has been variable depending on the demographical profile, economic status, and health care infrastructure. In the current clinical environment, COVID-19 is one of the most important clinical differential diagnoses in patients presenting with respiratory symptoms. The optimal mechanical ventilation strategy for these patients has been a constant topic of discussion and very importantly so, since a great majority of these patients require invasive mechanical ventilation and often for an extended period of time. In this report we highlight our experience with a COVID-19 patient who most likely suffered barotrauma either as a result of traumatic endotracheal intubation or primarily due to COVID-19 itself. We also aim to highlight the current literature available to suggest the management strategy for these patients for a favorable outcome. The cases described are diverse in terms of age variance and other comorbidities. According to the literature, certain patients, with COVID-19 disease and spontaneous pneumothorax were noted to be managed conservatively and oxygen supplementation with nasal cannula sufficed. Decision regarding need and escalation to invasive mechanical ventilation should be taken early in the disease to avoid complications such as patient self-inflicted lung injury (P-SILI) and barotrauma sequelae such as pneumothorax and pneumomediastinum Recent systematic review further supports the fact that the use of non-invasive ventilation (NIV) in certain patients with COVID-19 pneumonia may give a false sense of security and clinical stabilization but has no overall benefit to avoid intubation. While invasive mechanical ventilation may be associated with higher rates of barotrauma, this should not mean that intubation and invasive mechanical ventilation should be delayed. This becomes an important consideration when non-intensivists or personnel with less experience provide care for this vulnerable patient population who may rely too heavily on NIV to avoid intubation and mechanical ventilation.

Entities:  

Year:  2021        PMID: 33926176     DOI: 10.4081/monaldi.2021.1608

Source DB:  PubMed          Journal:  Monaldi Arch Chest Dis        ISSN: 1122-0643


  3 in total

1.  Incidence of Pneumothorax and Pneumomediastinum in 497 COVID-19 Patients with Moderate-Severe ARDS over a Year of the Pandemic: An Observational Study in an Italian Third Level COVID-19 Hospital.

Authors:  Nardi Tetaj; Gabriele Garotto; Fabrizio Albarello; Annelisa Mastrobattista; Micaela Maritti; Giulia Valeria Stazi; Maria Cristina Marini; Ilaria Caravella; Manuela Macchione; Giada De Angelis; Donatella Busso; Rachele Di Lorenzo; Silvana Scarcia; Anna Farina; Daniele Centanni; Joel Vargas; Martina Savino; Alessandro Carucci; Andrea Antinori; Fabrizio Palmieri; Gianpiero D'Offizi; Stefania Ianniello; Fabrizio Taglietti; Paolo Campioni; Francesco Vaia; Emanuele Nicastri; Enrico Girardi; Luisa Marchioni
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

2.  Pulmonary Barotrauma in COVID-19 Patients: Experience From a Secondary Care Hospital in Oman.

Authors:  Rasathurai Kajenthiran; Manish Kumar Tiwary; Ashok Lal; Jacob Paul; Faisal Al Sawafi; Yogesh Manhas; Ajay Yadav; Zaina Al Harthi; Abhijit Nair
Journal:  Cureus       Date:  2022-06-29

3.  Pre-hospital Aspirin Use and Patient Outcomes in COVID-19: Results from the International Viral Infection and Respiratory Illness Universal Study (VIRUS).

Authors:  Amos Lal; Juan Pablo Domecq Garces; Vikas Bansal; Aysun Tekin; Simon Zec; Ashish K Khanna; Matthew A Warner; Amy B Christie; Rodrigo Cartin-Ceba; Valerie M Banner-Goodspeed; Donna Lee Armaignac; Sreekanth R Cheruku; Umamaheswara Raju; Yasir Tarabichi; Joshua L Denson; Vishakha Kumar; Allan Walkey; Karen Boman; Neha Deo; Rahul Kashyap; Ognjen Gajic
Journal:  Arch Bronconeumol       Date:  2022-09-08       Impact factor: 6.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.